Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy : a retrospective study from a single cancer center
© 2023. The Author(s)..
OBJECTIVE: To investigate the role of consolidative thoracic radiation (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy followed by immunotherapy maintenance.
PATIENTS AND METHODS: Outcomes of patients without disease progression after first-line chemotherapy were retrospectively reviewed (January 2020 to December 2021). Based on TRT or not, patients were allocated to TRT group or non-TRT group. Progression-free survival (PFS), overall survival (OS) and local-recurrence free survival (LRFS) were calculated by the Kaplan-Meier method and compared by log-rank test.
RESULTS: Of 100 patients, 47 received TRT and 53 non-TRT. The median follow-up was 20.3 months. The median PFS and OS in TRT were 9.1 months and 21.8 months, versus 8.8 months (p = 0.93) and 24.3 months (p = 0.63), respectively, in non-TRT. The median LRFS time in TRT was not reached, but significantly longer than 10.8 months in non-TRT (HR = 0.27, p < 0.01). Second-line chemotherapy significantly prolonged survival compared to that with chemo-free patients (mOS: 24.5 vs. 21.4 months, p = 0.026). The subgroup analysis showed a trend of patients with brain metastases benefit from TRT (21.8 versus 13.7 months, HR 0.61, p = 0.38) while liver metastases did not. Of 47 patients with TRT, only 10.6% of patients experienced grade 3 radiation-induced pneumonitis, while no grade 4 or 5 adverse events occurred.
CONCLUSION: Consolidative TRT in the period of immunotherapy maintenance followed first-line chemo-immunotherapy did not prolong OS and PFS but associated with improved LRFS in ES-SCLC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Discover. Oncology - 14(2023), 1 vom: 04. Mai, Seite 55 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Yuying [VerfasserIn] |
---|
Links: |
---|
Themen: |
Immunotherapy |
---|
Anmerkungen: |
Date Revised 08.05.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1007/s12672-023-00666-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM356461297 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM356461297 | ||
003 | DE-627 | ||
005 | 20231226070518.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12672-023-00666-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1188.xml |
035 | |a (DE-627)NLM356461297 | ||
035 | |a (NLM)37142872 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Yuying |e verfasserin |4 aut | |
245 | 1 | 0 | |a Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy |b a retrospective study from a single cancer center |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 08.05.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a OBJECTIVE: To investigate the role of consolidative thoracic radiation (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy followed by immunotherapy maintenance | ||
520 | |a PATIENTS AND METHODS: Outcomes of patients without disease progression after first-line chemotherapy were retrospectively reviewed (January 2020 to December 2021). Based on TRT or not, patients were allocated to TRT group or non-TRT group. Progression-free survival (PFS), overall survival (OS) and local-recurrence free survival (LRFS) were calculated by the Kaplan-Meier method and compared by log-rank test | ||
520 | |a RESULTS: Of 100 patients, 47 received TRT and 53 non-TRT. The median follow-up was 20.3 months. The median PFS and OS in TRT were 9.1 months and 21.8 months, versus 8.8 months (p = 0.93) and 24.3 months (p = 0.63), respectively, in non-TRT. The median LRFS time in TRT was not reached, but significantly longer than 10.8 months in non-TRT (HR = 0.27, p < 0.01). Second-line chemotherapy significantly prolonged survival compared to that with chemo-free patients (mOS: 24.5 vs. 21.4 months, p = 0.026). The subgroup analysis showed a trend of patients with brain metastases benefit from TRT (21.8 versus 13.7 months, HR 0.61, p = 0.38) while liver metastases did not. Of 47 patients with TRT, only 10.6% of patients experienced grade 3 radiation-induced pneumonitis, while no grade 4 or 5 adverse events occurred | ||
520 | |a CONCLUSION: Consolidative TRT in the period of immunotherapy maintenance followed first-line chemo-immunotherapy did not prolong OS and PFS but associated with improved LRFS in ES-SCLC | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Immunotherapy | |
650 | 4 | |a Small-cell lung cancer | |
650 | 4 | |a Survival | |
650 | 4 | |a Thoracic radiation | |
650 | 4 | |a Toxicity | |
700 | 1 | |a Jing, Wang |e verfasserin |4 aut | |
700 | 1 | |a Jing, Xuquan |e verfasserin |4 aut | |
700 | 1 | |a Sun, Yulan |e verfasserin |4 aut | |
700 | 1 | |a Tang, Xiaoyong |e verfasserin |4 aut | |
700 | 1 | |a Guo, Jun |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Yan |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Hui |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Discover. Oncology |d 2021 |g 14(2023), 1 vom: 04. Mai, Seite 55 |w (DE-627)NLM323997384 |x 2730-6011 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:04 |g month:05 |g pages:55 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12672-023-00666-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2023 |e 1 |b 04 |c 05 |h 55 |